Document is current
Any future updates will be listed below
-
Authors
Padilla-Galo, A. http://orcid.org/0000-0003-4625-2716
García-Ruiz, A. J.
Levy Abitbol, R. Ch.
Olveira, C.
Rivas-Ruiz, F.
García-Agua Soler, N.
Pérez Morales, M.
Valencia Azcona, B.
Tortajada-Goitia, B.
Moya-Carmona, I.
Levy-Naon, A.
- License Information
-
More Information
Article History
Received: 2 March 2021
Accepted: 19 May 2021
First Online: 27 May 2021
Declarations
:
: Written informed consent was obtained from all participants. The study was reviewed by the Spanish Medicines and Health Products Agency and approved by the ethics committee <i>Comité de ética provincial de Málaga</i> (Approval: SNH-BEN-2020-01).
: Not applicable.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: APG reports personal fees and non-financial support from NOVARTIS, personal fees from ASTRA-ZENECA, personal fees and non-financial support from GSK, and personal fees from TEVA. CO reports non-financial support from NOVARTIS and personal fees and non-financial support from TEVA. ALN reports personal fees and non-financial support from NOVARTIS, personal fees from ASTRA-ZENECA, personal fees and non-financial support from GSK, and personal fees from TEVA.Other authors have no relevant COIs to disclose outside the submitted work.
